17.4.2023 21:20:51 CEST | Demant A/S |
Intern viden
Selskabsmeddelelse nr. 2023-06 17. april 2023
Demant opjusterer forventningerne til 2023
Demant offentliggør i dag foreløbige omsætnings- og væksttal for Q1 2023 og justerer forventningerne til 2023 som følge af meget stærke resultater i Q1. Forventningerne til den organiske vækst øges til 6-10 % (tidl. 3-7 %), og forventningerne til EBIT øges til DKK 3.800-4.200 mio. (tidl. DKK 3.600-4.000 mio.).
Omsætning (DKK mio.)
Vækst
Forretningsområde
Q1 2023
Q1 2022
Organisk
Akkvisitiv
LCY
FX
Rapporteret
Hearing Aids, samlet salg
3.048
2.351
26 %
0 %
26 %
4 %
30 %
Hearing Aids, internt salg
-570
-441
23 %
5 %
29 %
1 %
29 %
Hearing Aids, eksternt salg
2.478
1.910
26 %
-1 %
25 %
4 %
30 %
Hearing Care
2.218
1.898
9 %
8 %
17 %
0 %
17 %
Diagnostics
566
503
4 %
7 %
11 %
2 %
13 %
Hearing Healthcare
5.262
4.311
16 %
4 %
20 %
2 %
22 %
Communications
246
292
-15 %
0 %
-15 %
-1 %
-16 %
Koncern
5.508
4.603
14 %
4 %
18 %
2 %
20 %
I Q1 2023 realiserede Demant organisk vækst på 14 %. Dette var betydeligt over vores oprindelige forventninger som følge af meget stærke resultater i Hearing Healthcare, hvorimod Communications som forventet oplevede negativ organisk vækst.
Væksten i Hearing Aids lå betydeligt over vores oprindelige forventninger til Q1 som følge af meget stærke resultater i USA. Væksten var drevet af meget succesfulde lanceringer af nye højkvalitetshøreapparater i alle vores brands, deriblandt vores nye flagskibsprodukt, Oticon Real. Hearing Aids oplevede også stærkere end forventet vækst i Europa og Asien, hvilket afspejler bredt funderet kommercielt momentum. Samlet set var væksten hovedsageligt drevet af stykvækst, men også af en positiv udvikling i den gennemsnitlige salgspris.
Hearing Care leverede ligeledes stærkere end forventede resultater i Q1 takket være solid organisk vækst på de fleste større markeder. I Kina var den akkvisitive vækst efter opkøbet af Sheng Wang højere end forventet drevet af kraftig bedring efter betydelig negativ påvirkning fra coronavirus i begyndelsen af året.
I Diagnostics var den organiske vækst i Q1 negativt påvirket af nogle leveringsforsinkelser i forbindelse med ramp-up af en ny fabrik i Polen. Ordrebogen er imidlertid stadig godt fyldt op, og produktions-runraten var normaliseret i slutningen af Q1.
Som forventet oplevede Communications negativ organisk vækst i Q1 som følge af fortsat svage markeder for både enterprise solutions- og gaming-headset.
Drevet af udviklingen i Q1 2023 opjusterer vi vores forventninger til den organiske vækst til 6-10 % (tidl. 3-7 %). Derudover øger vi vores forventninger til EBIT til DKK 3.800-4.200 mio. (tidl. DKK 3.600-4.000 mio.), hvilket afspejler øget lønsomhed i Q1. Koncernens gearing-multipel ultimo 2023 forventes derfor nu at ligge inden for vores mellem- til langsigtede mål på 2,0-2,5.
Demant vil ikke afholde en telekonference i forbindelse med dagens meddelelse, men yderligere detaljer vil blive offentliggjort i vores periodemeddelelse den 3. maj 2023.
Yderligere information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Trine Kromann-Mikkelsen, VP Corporate Communication and Sustainability
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
2023-06 Demant opjusterer forventningerne til 2023.pdf
17.4.2023 21:20:51 CEST | Demant A/S |
Inside information
Company announcement no 2023-06 17 April 2023
Demant raises financial guidance for 2023
Today, Demant announces preliminary revenue and growth rates for Q1 2023 and adjusts the outlook for 2023 to reflect very strong performance in Q1. The outlook for organic growth is increased to 6-10% (prev. 3-7%) and for EBIT to DKK 3,800-4,200 million (prev. DKK 3,600-4,000 million).
Revenue (DKK million)
Growth
Business area
Q1 2023
Q1 2022
Organic
Acquisitive
LCY
FX
Reported
Hearing Aids, total sales
3,048
2,351
26%
0%
26%
4%
30%
Hearing Aids, internal sales
-570
-441
23%
5%
29%
1%
29%
Hearing Aids, external sales
2,478
1,910
26%
-1%
25%
4%
30%
Hearing Care
2,218
1,898
9%
8%
17%
0%
17%
Diagnostics
566
503
4%
7%
11%
2%
13%
Hearing Healthcare
5,262
4,311
16%
4%
20%
2%
22%
Communications
246
292
-15%
0%
-15%
-1%
-16%
Group
5,508
4,603
14%
4%
18%
2%
20%
In Q1 2023, Demant realised organic growth of 14%. This was significantly above our initial expectations driven by very strong performance in Hearing Healthcare, while Communications, as expected, saw negative organic growth.
Growth in Hearing Aids was significantly above initial expectations in Q1 driven by very strong performance in the US. Growth was fuelled by very successful launches of new premium hearing aids in all our brands, including our new flagship product, Oticon Real. Hearing Aids also saw stronger-than-expected growth in Europe and Asia, reflecting broad-based commercial momentum. Overall, growth was driven mostly by unit growth but also by positive ASP development.
Hearing Care also delivered stronger-than-expected performance in Q1 thanks to solid organic growth in most major markets. In China, acquisitive growth from Sheng Wang was higher than expected due to strong recovery following significant negative impacts of coronavirus at the beginning of the year.
In Diagnostics, organic growth in Q1 was negatively impacted by some shipment delays in connection with the ramp-up of a new production site in Poland. However, the order book remains strong and the production run rate had normalised at the end of Q1.
As expected, organic growth in Communications was negative in Q1 due to continuously weak markets for both enterprise solutions and gaming headsets.
Driven by the development in Q1 2023, we increase our outlook for organic growth to 6-10% (prev. 3-7%). Also, we increase our outlook for EBIT to DKK 3,800-4,200 million (prev. DKK 3,600-4,000 million), which reflects increased profitability in Q1. As a consequence, the Group’s gearing multiple at the end of 2023 is now expected to be within our medium- to long-term target of 2.0-2.5.
We will not host a conference call in connection with today’s announcement, but more details will be published in our Interim Management Statement on 3 May 2023.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Trine Kromann-Mikkelsen, VP Corporate Communication and Sustainability
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
2023-06 Demant raises financial guidance for 2023.pdf
